Role of BRAF and MEK Inhibitors in Pediatric Low-Grade Gliomas
Paediatrics
Pediatric low-grade gliomas (pLGGs) are frequently driven by alterations in the RAS/MAPK signalling pathway, particularly BRAF mutations and gene fusions. Molecular profiling has enabled the development of targeted therapies that inhibit BRAF and downstream MEK activity, offering new treatment options for selected children. The combination of dabrafenib and trametinib has demonstrated clinical benefit in BRAF V600E-mutated tumours, while MEK inhibitors such as selumetinib have shown activity in other molecular subgroups. Understanding biomarker testing, patient selection, treatment response, resistance mechanisms and long-term toxicity is essential for integrating targeted therapy into paediatric neuro-oncology practice. Please participate in the survey and share your opinion on role of BRAF and MEK inhibitors in pediatric low-grade gliomas.
In your opinion, which combination is more suitable for treating BRAF V600E-mutated pLGG requiring systemic therapy?
- Dabrafenib + Trametinib
- Vemurafenib + Selumetinib
- Dabrafenib + Selumetinib
- Trametinib monotherapy
Do you think targeted therapy can reduce the need for conventional chemotherapy or radiotherapy in selected children with pLGG?
- Strongly agree
- Agree
- Disagree
- Not sure